AstraZeneca (LON:AZN) Stock Rating Reaffirmed by DZ Bank

AstraZeneca (LON:AZN)‘s stock had its “sell” rating reiterated by stock analysts at DZ Bank in a research report issued on Monday, Borsen Zeitung reports.

Several other research analysts also recently commented on AZN. Kepler Capital Markets set a GBX 9,200 ($120.20) price objective on shares of AstraZeneca and gave the company a “buy” rating in a research report on Monday. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a £102 ($133.26) price objective on shares of AstraZeneca in a research report on Thursday, April 8th. Barclays set a £100 ($130.65) price objective on shares of AstraZeneca and gave the company a “buy” rating in a research report on Monday, March 22nd. UBS Group set a GBX 8,000 ($104.52) price target on shares of AstraZeneca and gave the stock a “buy” rating in a report on Friday, April 30th. Finally, Citigroup reiterated a “buy” rating on shares of AstraZeneca in a report on Wednesday, February 24th. Four investment analysts have rated the stock with a sell rating and fourteen have given a buy rating to the stock. AstraZeneca currently has an average rating of “Buy” and an average target price of GBX 8,886.25 ($116.10).

Shares of AZN opened at GBX 7,629 ($99.67) on Monday. AstraZeneca has a one year low of GBX 6,736 ($88.01) and a one year high of £101.20 ($132.22). The company has a market cap of £100.15 billion and a P/E ratio of 34.76. The company has a debt-to-equity ratio of 155.65, a current ratio of 0.87 and a quick ratio of 0.67. The firm has a 50 day simple moving average of GBX 7,333 and a two-hundred day simple moving average of GBX 7,569.54.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases.

Recommended Story: Benefits of owning preferred stock

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.